The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.
Jie MeiYun CaiLingyan ChenYouqing WuJiayu LiuZhiwen QianYing JiangPing ZhangTiansong XiaXiang PanYan ZhangPublished in: British journal of cancer (2023)
The CRABP2/CD69 signature is significantly associated with the TIME features and could effectively predict the clinical outcome. Also, CRABP2 is determined to be a novel oncogene, which could be a therapeutic target in BrCa.